A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Public ClinicalTrials.gov record NCT01766336. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
Study identification
- NCT ID
- NCT01766336
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 296 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 95 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2013 (Type not available)
- Primary completion
- Aug 2015 (Actual)
- Completion
- Aug 2015 (Actual)
- Last update posted
- Oct 21, 2019
2013 – 2015
United States locations
- U.S. sites
- 40
- U.S. states
- 19
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TransitionTIL Investigational Site | Birmingham | Alabama | 35294 | — |
| TransitionTIL Investigational Site | Phoenix | Arizona | 85004 | — |
| TransitionTIL Investigational Site | Phoenix | Arizona | 85006 | — |
| TransitionTIL Investigational Site | Encino | California | 91316 | — |
| TransitionTIL Investigational Site | Escondido | California | 92025 | — |
| TransitionTIL Investigational Site | Fresno | California | 93710 | — |
| TransitionTIL Investigational Site | Long Beach | California | 90806 | — |
| TransitionTIL Investigational Site | Newport Beach | California | 92658 | — |
| TransitionTIL Investigational Site | Orange | California | 92868 | — |
| TransitionTIL Investigational Site | Norwalk | Connecticut | 06851 | — |
| TransitionTIL Investigational Site | Washington D.C. | District of Columbia | 20057 | — |
| TransitionTIL Investigational Site | Atlantis | Florida | 33462 | — |
| TransitionTIL Investigational Site | Deerfield Beach | Florida | 33064 | — |
| TransitionTIL Investigational Site | Delray Beach | Florida | 33445 | — |
| TransitionTIL Investigational Site | Lake Worth | Florida | 33449 | — |
| TransitionTIL Investigational Site | Oakland Park | Florida | 33334 | — |
| TransitionTIL Investigational Site | Orlando | Florida | 32806 | — |
| TransitionTIL Investigational Site | Port Charlotte | Florida | 33952 | — |
| TransitionTIL Investigational Site | Sarasota | Florida | 34243 | — |
| TransitionTIL Investigational Site | Columbus | Georgia | 31909 | — |
| TransitionTIL Investigational Site | Savannah | Georgia | 31419 | — |
| TransitionTIL Investigational Site | Springfield | Illinois | 62702 | — |
| TransitionTIL Investigational Site | Easton | Maryland | 21601 | — |
| TransitionTIL Investigational Site | Winchester | Massachusetts | 01890 | — |
| TransitionTIL Investigational Site | Saint Paul | Minnesota | 55130 | — |
| TransitionTIL Investigational Site | Rochester | New York | 14620 | — |
| TransitionTIL Investigational Site | Rochester | New York | 14623 | — |
| TransitionTIL Investigational Site | Charlotte | North Carolina | 28211 | — |
| TransitionTIL Investigational Site | Durham | North Carolina | 27710 | — |
| TransitionTIL Investigational Site | Wilmington | North Carolina | 28401 | — |
| TransitionTIL Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| TransitionTIL Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| TransitionTIL Investigational Site | Portland | Oregon | 97225-6625 | — |
| TransitionTIL Investigational Site | Abington | Pennsylvania | 19001 | — |
| TransitionTIL Investigational Site | Jenkintown | Pennsylvania | 19046 | — |
| TransitionTIL Investigational Site | Norristown | Pennsylvania | 19401 | — |
| TransitionTIL Investigational Site | Pittsburgh | Pennsylvania | 15213 | — |
| TransitionTIL Investigational Site | Port Royal | South Carolina | 29935 | — |
| TransitionTIL Investigational Site | DeSoto | Texas | 75115 | — |
| TransitionTIL Investigational Site | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01766336, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2019 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01766336 live on ClinicalTrials.gov.